Evogene : Lavie Bio Company Presentation

Lavie Bio

Introduction

April 2021

Forward looking statement

This presentation contains "forward-looking statements" relating to future events, and Lavie Bio (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that

are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such

forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

2

The fork influences the farm

Consumer preferences drive change and impact how food is grown

Healthier

food

Sustainable

environment

Productive

agriculture

Better

value

3

Farmers200Baround the world invest*

$ +

annually in ag inputs to protect

and nurture their crops

$135B Chemical Fertilizers

55B Crop protection

$ chemicals

$8B Ag-Biological

4

* Company estimations

The Ag-Biologicals opportunity

Driving healthier produce, sustainability and productive agriculture

Driving crop productivity

New modes of action

Protect from resistance evolvement

Safe

Faster GTF (go to field)

Pesticides

~10-15 years | ~$250M

Cost

Microbiome

~5-8 years | <$15M

Time

Company estimations

Fastest growing ag. inputs segment

Wave 2

		$13.4B
	Wave 1
$3.2B	$7.0B
2015	2019E	2024E	5

*Source: MarketsandMarkets, industry publications